Testing for Teicoplanin Allergy Using Patients' Own Blood
Improving The Sensitivity of Teicoplanin Allergy Testing By Using Autologous Serum
NA · University Hospital Southampton NHS Foundation Trust · NCT06803758
This study is testing a new way to check if patients who had a serious allergic reaction to Teicoplanin are really allergic by using their own blood to make the allergy test more accurate.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Southampton NHS Foundation Trust (other) |
| Locations | 1 site (Southampton) |
| Trial ID | NCT06803758 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the reliability of allergy testing for Teicoplanin, a drug associated with serious allergic reactions. Patients who have experienced anaphylaxis during anesthesia and have received Teicoplanin will participate in the study. The approach involves mixing Teicoplanin with the patients' own blood to enhance the accuracy of skin testing. By doing so, the researchers hope to identify patients who are truly allergic to Teicoplanin, thereby preventing future life-threatening reactions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have experienced suspected anaphylaxis during anesthesia involving Teicoplanin.
Not a fit: Patients who are pregnant, under 18 years old, or have certain medical conditions that interfere with testing will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate allergy testing for Teicoplanin, reducing the risk of serious allergic reactions in patients.
How similar studies have performed: While allergy testing for other drugs has been reliable, this approach to Teicoplanin allergy testing is novel and has not been extensively tested before.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients 18 years old and above who have suffered suspected anaphylaxis under anaesthesia (the 'index episode'), where teicoplanin has been given Exclusion Criteria: * Patients unable to stop drugs that would interfere with skin tests prior to study- e.g. antihistamines or certain anti-psychotics * Pregnancy * Patients under age 18 years * Patients with elevated baseline mast cell tryptase requiring further investigation * Patients with blood-borne viruses such as Hep B, C and HIV
Where this trial is running
Southampton
- University Hospital Southampton — Southampton, United Kingdom (RECRUITING)
Study contacts
- Study coordinator: Linda Nel, MB BCh FRCA
- Email: linda.nel@uhs.nhs.uk
- Phone: 07957543839
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Drug Allergy, Teicoplanin allergy testing, Autologous Serum